Mostrar el registro sencillo del ítem

dc.contributor.author
Talevi, Alan  
dc.contributor.author
Bellera, Carolina Leticia  
dc.contributor.other
Talevi, Alan  
dc.date.available
2021-12-17T11:53:41Z  
dc.date.issued
2021  
dc.identifier.citation
Talevi, Alan; Bellera, Carolina Leticia; Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient; Springer Nature Switzerland AG; 2021; 1-6  
dc.identifier.isbn
978-3-030-51519-5  
dc.identifier.uri
http://hdl.handle.net/11336/148932  
dc.description.abstract
The brain-to-plasma concentration ratio (or totalbrain-to-plasma ratio, or simply, brain-to-plasma ratio, Kp, also referred toas B/P ratio or BB) is, as suggested by the name, the ratio between the total(bound and unbound) brain concentration Cbrain,ss and the total blood concentrationCblood.ss, at (pseudo)distribution equilibrium (steady state):Kp=Cbrain,ssCblood,ss(1) Kp has been extensively used atpreclinical drug development as an index of blood-brain barrier permeabilityand central nervous system (CNS) exposure. Alternatively to Eq. 1, it can alsobe computed as: Kp=AUCbrain,ssAUCblood,ss (2), where AUCbrain,ss denotes thearea under the curve of total concentrations in the brain (at steady state) andAUCblood,ss represents the area under the curve of total concentrations inblood (also at steady state). Often, Kp has been measured based on a crudehomogenization of brain tissue. Despite how tempting it may be to guidecompound optimization applying rapid in vitro assays, there is currentconsensus that the unbound brain-to-plasma ratio Kp,uu is much more relevant(or biorelevant) from a pharmacological perspective, as this parameter oftenshows a better correlation with receptor occupancy and other pharmacodynamicreadouts. This is because the magnitude of a pharmacological effect typicallydepends on the unbound (or free) drug levels in the biophase, and not on thetotal drug concentration. Since Kp is heavily influenced by nonspecificbinding, the efforts to optimize this parameter may in fact lead to anunproductive or even counterproductive design of drugs that have a high degreeof nonspecific (and pharmacodynamically inert) partitioning into brain tissue.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Springer Nature Switzerland AG  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
BRAIN BIOAVAILABILITY  
dc.subject
CNS BIOAVAILABILITY  
dc.subject
CENTRAL NERVOUS SYSTEM  
dc.subject
DRUG BIOAVAILABILITY  
dc.subject.classification
Otras Ciencias Biológicas  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.type
info:eu-repo/semantics/bookPart  
dc.type
info:ar-repo/semantics/parte de libro  
dc.date.updated
2021-11-17T14:51:46Z  
dc.journal.pagination
1-6  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Basignstoke  
dc.description.fil
Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina  
dc.description.fil
Fil: Bellera, Carolina Leticia. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://doi.org/10.1007/978-3-030-51519-5_61-1  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/referenceworkentry/10.1007%2F978-3-030-51519-5_61-1  
dc.conicet.paginas
1500  
dc.source.titulo
The ADME encyclopedia